p38 and JNK induction by TRAIL 20. Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C et al. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 2011; 105(10):1542‐1553. 21. Voortman J, Resende TP, bou El Hassan MA, Giaccone G, Kruyt FA. TRAIL <strong>therapy</strong> in non‐ small cell lung cancer cells: sensitization to <strong>death</strong> <strong>receptor</strong>‐mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007; 6(7):2103‐2112. 22. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor‐related apoptosis‐inducing ligand. J Biol Chem 2005; 280(49):40599‐40608. 23. Krishna M, Narang H. The complexity of mitogen‐activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 2008; 65(22):3525‐3544. 24. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. SP600125, an anthrapyrazolone inhibitor of Jun N‐terminal kinase. Proc Natl Acad Sci U S A 2001; 98(24):13681‐13686. 25. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D et al. Pyridinyl imidazole inhibitors of p38 mitogen‐activated protein kinase bind in the ATP site. J Biol Chem 1997; 272(18):12116‐12121. 26. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998; 6(9):1117‐1128. 27. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4(5):313‐321. 28. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemo<strong>therapy</strong> triggers apoptosis in a caspase‐8‐dependent and mitochondria‐controlled manner in the non‐small cell lung cancer cell line NCI‐H460. Cancer Res 2000; 60(24):7133‐7141. 29. Son JK, Varadarajan S, Bratton SB. TRAIL‐activated stress kinases suppress apoptosis through transcriptional upregulation of MCL‐1. Cell Death Differ 2010; 17(8):1288‐1301. 30. Trouillas M, Saucourt C, Duval D, Gauthereau X, Thibault C, Dembele D et al. Bcl2, a transcriptional target of p38alpha, is critical <strong>for</strong> neuronal commitment of mouse embryonic stem cells. Cell Death Differ 2008; 15(9):1450‐1459. 31. Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL <strong>receptor</strong> targeting therapies <strong>for</strong> non‐small cell lung cancer: current status and perspectives. Drug Resist Updat 2010; 13(1‐2):2‐15. 32. Zhang L, Fang B. Mechanisms of resistance to TRAIL‐induced apoptosis in cancer. Cancer Gene Ther 2005; 12(3):228‐237. 33. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK‐activated protein kinases. Microbiol Mol Biol Rev 2011; 75(1):50‐83. 34. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14(3):400‐410. 35. Lin Y, Devin A, Rodriguez Y, Liu ZG. Cleavage of the <strong>death</strong> domain kinase RIP by caspase‐8 prompts TNF‐induced apoptosis. Genes Dev 1999; 13(19):2514‐2526. 36. Martinon F, Holler N, Richard C, Tschopp J. Activation of a pro‐apoptotic amplification loop through inhibition of NF‐kappaB‐dependent survival signals by caspase‐mediated inactivation of RIP. FEBS Lett 2000; 468(2‐3):134‐136. 37. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S et al. The <strong>death</strong> domain kinase RIP is essential <strong>for</strong> TRAIL (Apo2L)‐induced activation of IkappaB kinase and c‐Jun N‐terminal kinase. Mol Cell Biol 2000; 20(18):6638‐6645. 38. Thomas LW, Lam C, Edwards SW. Mcl‐1; the molecular regulation of protein function. FEBS Lett 2010; 584(14):2981‐2989. 39. Zhong Q, Gao W, Du F, Wang X. Mule/ARF‐BP1, a BH3‐only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl‐1 and regulates apoptosis. Cell 2005; 121(7):1085‐1095. ‐ 57 ‐
Chapter 3 40. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004; 23(31):5301‐5315. 41. Kodama Y, Taura K, Miura K, Schnabl B, Osawa Y, Brenner DA. Antiapoptotic effect of c‐Jun N‐terminal Kinase‐1 through Mcl‐1 stabilization in TNF‐induced hepatocyte apoptosis. Gastroenterology 2009; 136(4):1423‐1434. 42. Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D et al. TRAIL <strong>receptor</strong>‐mediated JNK activation and Bim phosphorylation critically regulate Fas‐mediated liver damage and lethality. J Clin Invest 2006; 116(9):2493‐2499. 43. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. c‐Jun N‐terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta 2010; 1804(3):463‐475. 44. Mahalingam D, Keane M, Pirianov G, Mehmet H, Samali A, Szegezdi E. Differential activation of JNK1 iso<strong>for</strong>ms by TRAIL <strong>receptor</strong>s modulate apoptosis of colon cancer cell lines. Br J Cancer 2009; 100(9):1415‐1424. ‐ 58 ‐
Change language